NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...
Press Releases
EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation
NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...
Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo
NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...
EVQLV, Manhattan BioSolutions Enter Strategic Collaboration to Discover Novel Antibody Therapies
EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a strategic research collaboration with Manhattan BioSolutions, Inc., a biotechnology company focused on developing next-generation therapies for...
EVQLV’s Collaboration with Twist Bioscience aims to Discover and Validate Novel Antibody Therapies
NEW YORK, NY and SOUTH SAN FRANCISCO, Calif – July 7, 2020 -- EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling...